Eyenovia Appoints Three Industry Veterans to Board of Directors
March 26 2018 - 4:05PM
Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage biopharmaceutical
company developing a pipeline of ophthalmology products utilizing
its patented piezo-print technology to deliver micro-therapeutics
topically to the eye, today announced that it has appointed
directors Kenneth B. Lee, Jr., Charles E. Mather IV and Anthony Y.
Sun, as independent members of its Board of Directors, effective
immediately.
Mr. Lee will serve as Chairman of the Audit
Committee and Dr. Sun will chair the Compensation Committee.
Dr. Sean Ianchulev, Eyenovia’s Chief Executive
Officer and Chief Medical Officer commented, “We are pleased these
three industry veterans have joined our Board of Directors at such
an exciting time in Eyenovia’s history. They join a team that
brings a tremendous amount of experience to Eyenovia and we believe
that, together, we will help guide Eyenovia through our near and
long-term milestones. Following our successful IPO, we plan to
initiate phase 3 studies in two of our assets in the second half of
2018, bringing us closer to a therapeutic paradigm shift in
ophthalmology; and we believe our reinforced Board will help us
realize that potential.”
Mr. Lee, 70, has been a General Partner of
Hatteras Venture Partners, LLC, a venture capital fund focusing on
life science companies since January 2003. Previously he was
President of A.M. Pappas & Associates, LLC, following 29 years
with Ernst & Young LLP, where he was most recently Managing
Director of the firm’s health sciences corporate finance group, and
at one time served as the National Director of the Life Sciences
Practice. Mr. Lee serves on the boards of Aralez Pharmaceuticals,
Inc. (Nasdaq:ARLZ) and BioCryst Pharmaceuticals Inc. (Nasdaq:BCRX).
Previously, Mr. Lee has served on the boards of several private
companies and public companies, including Abgenix, Inc. (acquired
by Amgen, Inc.), CV Therapeutics Inc. (acquired by Gilead Sciences,
Inc.), Inspire Pharmaceuticals, Inc. (acquired by Merck &Co.,
Inc.), Maxygen, Inc. (dissolved) and OSI Pharmaceuticals, Inc.
(acquired by Astellas Pharma Inc.). Mr. Lee received a B.A. from
Lenoir-Rhyne College and an M.B.A. from the University of North
Carolina at Chapel Hill.
Mr. Mather, 57, has been Managing Director,
Co-Head of Equity Capital Markets at BTIG, LLC since March 2015.
From December 2009 to February 2015 he was the Head of Private and
Alternative Capital and Co-Head of Equity Capital Markets at Janney
Montgomery Scott, LLC. Between May 2007 and September 2008, Mr.
Mather was the head of the Structured Equity Group at Jefferies
Group Inc. Prior to that, Mr. Mather held various senior investment
banking positions at Cowen and Company, including as Co-Head of the
Private Equity Group. Mr. Mather serves on the board of Tonix
Pharmaceuticals Holdings Corp. (Nasdaq:TNXP) and Wentz LLC. Mr.
Mather also served on the board of the Finance Company of
Pennsylvania until August 2017. Mr. Mather received a B.A. in
History from Brown University and an M.B.A. in Finance from The
Wharton School at the University of Pennsylvania.
Dr. Sun, 46, is involved with many private
biotechnology companies. Dr. Sun was at Aisling Capital, a
private equity firm dedicated to life sciences, from September 2002
until May 2015, during which he held multiple positions most
recently as partner. Dr. Sun serves on the board of Versartis, Inc.
(Nasdaq:VSAR), Immusoft Corporation and several other private
companies. Dr. Sun holds a B.S. in Electrical Engineering from
Cornell University, an M.D. from Temple University School of
Medicine, an M.B.A. from The Wharton School at the University
of Pennsylvania, trained in internal medicine at the Hospital of
the University of Pennsylvania and was Board Certified in
Internal Medicine.
About Eyenovia
Eyenovia is a specialty biopharmaceutical
company building a portfolio of next generation topical eye
treatments based on its proprietary delivery and formulation
platform for micro-therapeutics. Eyenovia’s pipeline is currently
focused on the late-stage development of micro-therapeutics for
glaucoma and other eye diseases.
Forward-Looking Statements
Except for historical information, all of the
statements, expectations, and assumptions contained in this press
release are forward-looking statements. Forward-looking statements
include, but are not limited to, statements that express our
intentions, beliefs, expectations, strategies, predictions or any
other statements relating to our future activities or other future
events or conditions. These statements are based on current
expectations, estimates and projections about our business based,
in part, on assumptions made by management. These statements are
not guarantees of future performance and involve risks,
uncertainties and assumptions that are difficult to predict.
Therefore, actual outcomes and results may, and are likely to,
differ materially from what is expressed or forecasted in the
forward-looking statements due to numerous factors discussed from
time to time in documents which we file with the SEC. In addition,
such statements could be affected by risks and uncertainties
related to, among other things: our ability to attract and retain
key personnel; our clinical trials; the timing and our ability to
submit applications for, obtain and maintain regulatory approvals
for, our product candidates; our ability to implement our business
plan to commercialize our product candidates; the potential
advantages of our product candidates; the rate and degree of market
acceptance and clinical utility of our product candidates; our
estimates regarding the potential market opportunity for our
product candidates; our commercialization, marketing and
manufacturing capabilities and strategy; our ability to identify
additional products, product candidates or technologies with
significant commercial potential that are consistent with our
commercial objectives; our expectations regarding our ability to
fund our operating expenses and capital expenditure requirements;
intellectual property risks; the impact of government laws and
regulations; our competitive position; and general economic
conditions. Any forward-looking statements speak only as of the
date on which they are made, and except as may be required under
applicable securities laws, we do not undertake any obligation to
update any forward-looking statements.
Company Contact:Eyenovia
Inc.John GandolfoChief Financial
Officerjgandolfo@eyenoviabio.com
Investor Contact:Tram Bui /
Alexander LoboThe Ruth GroupPhone: 646-536-7035/7037E-mail:
tbui@theruthgroup.com / alobo@theruthgroup.com
Media Contact:The Ruth
GroupKirsten Thomas508-280-6592kthomas@theruthgroup.com
VERSARTIS, INC. (NASDAQ:VSAR)
Historical Stock Chart
From Sep 2024 to Oct 2024
VERSARTIS, INC. (NASDAQ:VSAR)
Historical Stock Chart
From Oct 2023 to Oct 2024